The Effect of Adjuvant Radiotherapy on One- and Two-Stage Prosthetic Breast Reconstruction and on Autologous Reconstruction: A Multicenter Italian Study Among 18 Senonetwork Breast Centres
Authors
Affiliations
Purpose: In modern breast cancer treatment, a growing role has been observed for breast reconstruction together with an increase in clinical indications for postmastectomy radiotherapy (PMRT). Choosing the optimum type of reconstructive technique is a clinical challenge. We therefore conducted a national multicenter study to analyze the impact of PMRT on breast reconstruction.
Methods: We conducted a retrospective case-control multicenter study on women undergoing breast reconstruction. Data were collected from 18 Italian Breast Centres and stored in a cumulative database which included the following: autologous reconstruction, direct-to-implant (DTI), and tissue expander/immediate (TE/I). For all patients, we described complications and surgical endpoints to complications such as reconstruction failure, explant, change in type of reconstruction, and reintervention.
Results: From 2001 to April 2020, 3116 patients were evaluated. The risk for any complication was significantly increased in patients receiving PMRT (aOR, 1.73; 95% CI, 1.33-2.24; < 0.001). PMRT was associated with a significant increase in the risk of capsular contracture in the DTI and TE/I groups (aOR, 2.24; 95% CI, 1.57-3.20; < 0.001). Comparing type of procedures, the risk of failure (aOR, 1.82; 95% CI, 1.06-3.12, =0.030), explant (aOR, 3.34; 95% CI, 3.85-7.83, < 0.001), and severe complications (aOR, 2.54; 95% CI, 1.88-3.43, < 0.001) were significantly higher in the group undergoing DTI reconstruction as compared to TE/I reconstruction.
Conclusion: Our study confirms that autologous reconstruction is the procedure least impacted by PMRT, while DTI appears to be the most impacted by PMRT, when compared with TE/I which shows a lower rate of explant and reconstruction failure. The trial is registered with NCT04783818, and the date of registration is 1 March, 2021, retrospectively registered.
Citgez B, Yigit B, Capkinoglu B, Altinkaya A Sisli Etfal Hastan Tıp Bul. 2025; 58(4):401-410.
PMID: 39816433 PMC: 11729833. DOI: 10.14744/SEMB.2024.34033.
Lisa A, Salgarello M, Huscher A, Corsi F, Piovani D, Rubbino F Breast J. 2023; 2023:6688466.
PMID: 37205012 PMC: 10188256. DOI: 10.1155/2023/6688466.